SP-102
/ Sumitomo Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 23, 2019
Talee Bio announces $4.5 million award from the cystic fibrosis foundation to advance development of two gene therapy product candidates
(Businesswire)
- “Talee Bio…announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102.”
Financing
January 23, 2019
Newly added product
(Businesswire)
- Preclinical, Cystic Fibrosis
Pipeline update
1 to 2
Of
2
Go to page
1